A Third Gene Editing IPO from CRISPR Therapeutics

September 14. 2016. 3 mins read

We’ve talked before about an exciting new technology called “gene editing” which is a tool that enables synthetic biology. Out of all the disruptive technologies out there, gene editing is perhaps the most mysterious at the moment. We’re not really sure what cool things we can do with gene editing and (listen up investors) we’re not really sure who owns this technology. That’s right. We’re in the midst of a patent dispute and it’s anybody’s guess as to who the winners will be. There could be more than one winner but there most likely will be at least one loser whose share price will suffer as the result of the eventual outcome.

Prior to this past week’s news, there were 2 stocks you could buy as a pure-play on the gene editing theme; Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutic (NASDAQ:NTLA). Here’s a look at how those share prices have performed since their respective IPOs:



So not the best post-IPO performance for these two stocks with EDIT losing -17%

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.